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Complement and
Correction for Meta-
Analysis of Patients
with Extensive-Stage
Small Cell Lung Cancer
Managed with
Irinotecan/Cisplatin
versus Etoposide/
Cisplatin as First-Line
Chemotherapy
To the Editor:
We read with great interest the
article by Jiang et al.1 on “A Meta-
Analysis of Randomized Controlled Tri-
als Comparing Irinotecan/Platinum with
Etoposide/Platinum in Patients with
Previously Untreated Extensive-Stage
Small Cell Lung Cancer” in the issue of
May 2010. We have identified a new
study published in 2010,2 after the liter-
ature search completion date (April
2009) of the report by Jiang et al., which
may result in outcome changes. We
complemented it using the same method
as Jiang et al. did for meta-analysis and
then excluded the trial using carboplatin
treatment that we believe caused bias,
especially in toxicities and responses.
Moreover, one trial was also not reason-
able for subgroup analysis.
The odds ratios (ORs) used to ex-
press results in toxicities in the article
was another problem. The OR is a rea-
sonable approximation of the relative
risk (RR) when the probability of posi-
tive response is small. However, OR
increases dramatically when the out-
come rate rises above 1%, and the RR
remains constant. The RR is easily in-
terpreted and more commonly used in
randomized controlled trials, whereas
the OR often expresses the association
between exposure and outcome in case-
control studies.3 Therefore, RR was
adopted in toxicities reanalysis.
We also reanalyzed the overall sur-
vival (OS), progression-free survival (PFS),
and overall responses with the trial used
excluding carboplatin. Data of six trials
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FIGURE 1. Relative risk (RR) plot for response and hazard ratio (HR) plots for
overall survival and progression-free survival.
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(1602 patients with extensive-stage small
cell lung cancer [E-SCLC]) were collected
and analyzed totally. Statistical analyses
were calculated using STATA SE 11.1.
RESPONSE
The meta-analysis demonstrated that
the irinotecan/cisplatin (IP) regimen ac-
quired more overall response than the eto-
poside/cisplatin (EP) regimen (RR  1.04,
95% confidence interval [CI]: 0.95–1.14,
p  0.0404; Figure 1). There was no het-
erogeneity (2  7.44; p  0.115), and
the pooled RR for overall response
was performed using fixed-effort model
(Figure 1).
OVERALL SURVIVAL
Hazard ratios (HRs) for OS were
available for four trials. The pooled HR
showed that there were no survival differ-
ences between the two regimens
in patients with previously untreated
E-SCLC (HR  0.83, 95% CI: 0.68–0.99,
p 0.052; Figure 1). There was significant
heterogeneity (2  8.73; p  0.033), and
the pooled HR for OS was performed using
random-effort model (Figure 1).
PROGRESSION-FREE SURVIVAL
Meta-analysis result showed that
the PFS between two arms was not sig-
nificantly different (HR  0.91, 95%
CI: 0.72–1.11, p  0.393; Figure 1).
There was significant heterogeneity
(2  13.63; p  0.003), and the pooled
HR for PFS was performed using ran-
dom-effort model (Figure 1).
TOXICITIES
The IP regimen led to less grade 3
to 4 neutropenia, thrombocytopenia, and
anemia (p  0.000, 0.004, 0.042, re-
spectively), while more grade 3 to 4
nausea/vomiting and diarrhea than the
EP regimen (p  0.014 and 0.000, re-
spectively) (Figure 2).
In conclusion, the results obtained
are a little different from Jiang et al. Ran-
domized evidence available for meta-anal-
ysis does not support the benefit of IP
regimen in OS and PFS, but it gains in
overall response. Furthermore, less hema-
tologic toxicity contributes a lot to patients
with poor bone marrow reserve. Conse-
quently, IP regimen might be an optional
chemotherapy for patients with previously
untreated E-SCLC.
FIGURE 2. The pooled relative risk for toxicities.
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In Response:
We thank Guo et al. for their com-
ment on our article entitled “A Meta-
Analysis of Randomized Controlled Trials
Comparing Irinotecan/Platinum with Eto-
poside/Platinum in Patients with Previ-
ously Untreated Extensive-Stage Small
Cell Lung Cancer.”1 The meta-analysis
was completely accepted for publication
in February 2010, and the new clinical
trial reported by Zatloukal et al.2 was
published online in March 2010; there-
fore, we were unable to add the new trial
to the meta-analysis. Both trials given
carboplatin or cisplatin were included
into the meta-analysis. We also per-
formed sensitivity analysis, after the
trial using carboplatin treatment was ex-
cluded, to identify whether there was
bias caused by different platinum. We
integrated two forest plots into one fig-
ure when the overall analysis and sensi-
tivity analysis were conducted. So, in
this figure, the subgroup of carboplatin
that included only one trial should be
considered as a removed trial by the
sensitivity analysis. This management
did not affect the results of overall anal-
ysis and sensitivity analysis.
Although there is some difference
in the odds ratio (OR) and relative risk
(RR), both OR and RR are effective
measures for dichotomous outcomes in
meta-analysis. The risk ratio (RR) is the
ratio of the risk of an event in the two
groups, whereas the OR is the ratio of
the odds of an event. For both measures,
a value of one indicates that the esti-
mated effects are the same for both treat-
ments, but the interpretation of an OR is
more complicated than for a RR (see
page 75 in Cochrane Reviewers’ Hand-
book 4.2.3). Our results calculated by
OR were also confirmed by RR.
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